Adaptimmune Therapeutics (ADAP) Competitors $0.06 +0.00 (+2.45%) Closing price 04:00 PM EasternExtended Trading$0.06 0.00 (-1.03%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. ANL, GANX, CVM, HOWL, IZTC, ADVM, INKT, UNCY, DRRX, and KALAShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), Invizyne Technologies (IZTC), Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Unicycive Therapeutics (UNCY), DURECT (DRRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Its Competitors Adlai Nortye Gain Therapeutics CEL-SCI Werewolf Therapeutics Invizyne Technologies Adverum Biotechnologies MiNK Therapeutics Unicycive Therapeutics DURECT KALA BIO Adlai Nortye (NASDAQ:ANL) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Is ANL or ADAP more profitable? Adlai Nortye has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -260.82%. Adlai Nortye's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Adaptimmune Therapeutics -260.82%-163.73%-75.83% Does the media refer more to ANL or ADAP? In the previous week, Adaptimmune Therapeutics had 11 more articles in the media than Adlai Nortye. MarketBeat recorded 12 mentions for Adaptimmune Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.47 beat Adaptimmune Therapeutics' score of 0.23 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptimmune Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ANL or ADAP? Adlai Nortye currently has a consensus target price of $9.00, suggesting a potential upside of 432.54%. Adaptimmune Therapeutics has a consensus target price of $1.35, suggesting a potential upside of 2,210.54%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings & valuation, ANL or ADAP? Adlai Nortye has higher earnings, but lower revenue than Adaptimmune Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M12.47-$51.87MN/AN/AAdaptimmune Therapeutics$178.03M0.09-$70.81M-$0.65-0.09 Which has more volatility & risk, ANL or ADAP? Adlai Nortye has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ANL or ADAP? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 12.7% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAdlai Nortye beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks. Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.51M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.0920.4330.4625.16Price / Sales0.09238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book-0.227.918.956.21Net Income-$70.81M-$54.72M$3.26B$265.38M7 Day PerformanceN/A1.66%1.06%-1.13%1 Month PerformanceN/A5.88%4.31%-0.71%1 Year PerformanceN/A8.72%28.39%18.86% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics2.1171 of 5 stars$0.06+2.5%$1.35+2,210.5%-94.6%$15.51M$178.03M-0.09490Insider TradeAnalyst RevisionGap DownHigh Trading VolumeANLAdlai Nortye1.3891 of 5 stars$1.77+4.8%$9.00+408.2%-41.8%$62.36M$5M0.00127Short Interest ↑Gap UpGANXGain Therapeutics2.3361 of 5 stars$1.77+2.3%$7.80+340.7%+27.2%$62.19M$50K-2.8120High Trading VolumeCVMCEL-SCI1.5991 of 5 stars$8.92+2.5%N/A-73.5%$61.39MN/A-18.5843HOWLWerewolf Therapeutics3.2719 of 5 stars$1.33flat$8.33+526.6%-40.7%$60.82M$1.88M-0.8140Earnings ReportAnalyst ForecastAnalyst RevisionIZTCInvizyne TechnologiesN/A$9.70-2.9%N/AN/A$60.64MN/A0.0029News CoverageADVMAdverum Biotechnologies3.8947 of 5 stars$2.93+2.4%$19.75+574.1%-59.8%$60.01M$1M-0.37190Analyst RevisionINKTMiNK Therapeutics2.9422 of 5 stars$14.62-1.9%$37.50+156.5%+72.5%$59.43MN/A-5.0830Earnings ReportAnalyst DowngradeUNCYUnicycive Therapeutics2.6522 of 5 stars$4.08-13.2%$60.00+1,370.6%+3.8%$59.41M$680K-0.999News CoverageEarnings ReportHigh Trading VolumeDRRXDURECT1.8251 of 5 stars$1.90-0.5%N/A+42.9%$59.31M$2.03M-19.0080Short Interest ↓KALAKALA BIO4.0899 of 5 stars$8.58+3.1%$13.00+51.5%+32.4%$58.42M$3.89M-1.2630 Related Companies and Tools Related Companies ANL Alternatives GANX Alternatives CVM Alternatives HOWL Alternatives IZTC Alternatives ADVM Alternatives INKT Alternatives UNCY Alternatives DRRX Alternatives KALA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access